Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study

被引:84
作者
Lencioni, Riccardo [1 ]
Crocetti, Laura [1 ]
Petruzzi, Pasquale [1 ]
Vignali, Claudio [1 ]
Bozzi, Elena [1 ]
Della Pina, Clotilde [1 ]
Bargellini, Irene [1 ]
Cion, Dania [1 ]
Oliveri, Filippo [2 ]
De Simone, Paolo [3 ]
Bartolozzi, Carlo [1 ]
Brunetto, Maurizia [2 ]
Filipponi, Franco [3 ]
机构
[1] Cisanello Univ Hosp, Dept Oncol & Radiol, Div Diagnost & Intervent Radiol, IT-56124 Pisa, Italy
[2] Cisanello Univ Hosp, Dept Liver Transplant Hepatol & Infect Dis, Div Hepatol, IT-56124 Pisa, Italy
[3] Cisanello Univ Hosp, Dept Liver Transplantat Hepatol & Infect Dis, Div Liver Transplantat, IT-56124 Pisa, Italy
关键词
hepatocellular carcinoma; radiofrequency ablation; doxorubicin;
D O I
10.1016/j.jhep.2008.03.021
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Experimental studies have shown synergy between radiofrequency (RF) ablation and adjuvant chemotherapy in animal turnout models. We aimed to assess safety and efficacy of doxorubicin-eluting bead (DEB)-enhanced RF ablation in the treatment of human hepatocellular carcinoma (HCC). Methods: Twenty patients with single HCC ranging 3.3-7.0 cm (mean, 5.0 cm +/- 1.4) showing evidence of residual viable tumour after standard RF ablation underwent intraarterial DEB administration (50-125 mg doxorubicin; mean, 60.2 mg +/- 21.8). Follow-up period ranged 6-20 months (mean, 12 months +/- 5). Results: No major complication occurred. No deterioration of liver function was observed. The volume of treatment-induced necrosis - as measured on imaging - increased from 48.1 cm(3) +/- 35.7 after RF ablation to 75.5 cm(3) + 52.4 after DEB administration, with an increase of 60.9% +/- 39.0. The enhanced effect resulted in confirmed complete response (CR) of the target lesion in 12 (60%) of 20 patients. Incomplete response with persistence of <10% of initial turnout volume was observed in 6 (30%) of 20 patients, and local turnout progression in 2 (10%) of 20. Conclusions:Intraarterial DEB administration substantially enhances the effect of RF ablation. DEB-enhanced RF ablation is safe and results in a high rate of CR in patients refractory to standard RF treatment. (C) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 27 条
[1]
Combination radiofrequency ablation with intratumoral liposomal doxorubicin: Effect on drug accumulation and coagulation in multiple tissues and tumor types in animals [J].
Ahmed, M ;
Liu, ZJ ;
Lukyanov, AN ;
Signoretti, S ;
Horkan, C ;
Monsky, WL ;
Torchilin, VP ;
Goldberg, SN .
RADIOLOGY, 2005, 235 (02) :469-477
[2]
Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[3]
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[4]
Radiofrequency ablation of hepatocellular carcinoma: Long-term experience with expandable needle electrodes [J].
Cabassa, P ;
Donato, F ;
Simeone, F ;
Grazioli, L ;
Romanini, L .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 186 (05) :S316-S321
[5]
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma [J].
Chen, MS ;
Li, JQ ;
Zheng, Y ;
Guo, RP ;
Liang, HH ;
Zhang, YQ ;
Lin, XJ ;
Lau, WY .
ANNALS OF SURGERY, 2006, 243 (03) :321-328
[6]
Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series [J].
Choi, Dongil ;
Lim, Hyo K. ;
Rhim, Hyunchul ;
Kim, Young-sun ;
Lee, Won Jae ;
Paik, Seung Woon ;
Koh, Kwang Cheol ;
Lee, Joon Hyoek ;
Choi, Moon Seok ;
Yoo, Byung Chul .
EUROPEAN RADIOLOGY, 2007, 17 (03) :684-692
[7]
Percutaneous radiofrequency tissue ablation: Does perfusion-mediated tissue cooling limit coagulation necrosis? [J].
Goldberg, SN ;
Hahn, PF ;
Tanabe, KK ;
Mueller, PR ;
Schima, W ;
Athanasoulis, CA ;
Compton, CC ;
Solbiati, L ;
Gazelle, GS .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1998, 9 (01) :101-111
[8]
Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance [J].
Goldberg, SN ;
Gazelle, GS ;
Mueller, PR .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2000, 174 (02) :323-331
[9]
Image-guided tumor ablation: Proposal for standardization of terms and reporting criteria [J].
Goldberg, SN ;
Charboneau, JW ;
Dodd, GD ;
Dupuy, DE ;
Gervais, DA ;
Gillams, AR ;
Kane, RA ;
Lee, FT ;
Livraghi, T ;
McGahan, JP ;
Rhim, H ;
Silverman, SG ;
Solbiati, L ;
Vogl, TJ ;
Wood, BJ .
RADIOLOGY, 2003, 228 (02) :335-345
[10]
Percutaneous tumor ablation: Increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model [J].
Goldberg, SN ;
Girnan, GD ;
Lukyanov, AN ;
Ahmed, M ;
Monsky, WL ;
Gazelle, GS ;
Huertas, JC ;
Stuart, KE ;
Jacobs, T ;
Torchillin, VP ;
Halpern, EF ;
Kruskal, JB .
RADIOLOGY, 2002, 222 (03) :797-804